Dermapharm Holding SE Achieves Top End of Guidance Range Amid Challenges

Dermapharm Holding SE, a burgeoning pharmaceutical and healthcare product manufacturer, has reported its unaudited preliminary consolidated figures for the financial year 2023. The company witnessed a revenue increase of 10.8%, reaching EUR 1,135.4 million, despite a 13.8% decrease in adjusted EBITDA to EUR 310.2 million. The adjusted consolidated EBITDA margin was reported at 27.3%. Notably, the Board of Management proposes a dividend of EUR 0.88 per share at the forthcoming Annual General Meeting.

Despite facing macroeconomic and geopolitical hurdles, including the aftermath of the coronavirus pandemic and the impact of Russia's invasion of Ukraine, Dermapharm's business model showcased resilience. The company attributed its success to the acquisition of Arkopharma and organic growth within its existing portfolio. The "Other healthcare products" segment experienced notable growth, benefiting from the incorporation of Arkopharm Group. However, the "Parallel import business" segment saw a slight decline in revenue and EBITDA mainly due to increased manufacturers' rebates and product shortages in the parallel import market.

Looking ahead, Dermapharm anticipates further growth in the financial year 2024, with estimated consolidated revenue ranging between EUR 1,170 million and EUR 1,210 million and adjusted consolidated EBITDA projected to be between EUR 305 million and EUR 315 million. The finalized audited figures for 2023 and the comprehensive annual report will be released on 28 March 2024.